Involvement of reactive oxygen species in adaphostin-induced cytotoxicity in human leukemia cells

Blood

Volumn 102, Issue 13, 2003, Pages 4512-4519

  Chandra, Joya ^b   Hackbarth, Jennifer ^b   Le, Son ^b   Loegering, David ^b   Bone, Nancy ^b   Bruzek, Laura M ^b   Narayanan, Ven L ^b   Adjei, Alex A ^b   Kay, Neil E ^b   Tefferi, Ayalew ^b   Karp, Judith E ^b   Sausville, Edward A ^b   Kaufmann, Scott H ^a  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ADAPHOSTIN; AG 957; BCR ABL PROTEIN; BUTHIONINE SULFOXIMINE; CYTOTOXIC AGENT; DNA; GLUTATHIONE; IMATINIB; NSC 676537; PEROXIDE; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TYRPHOSTIN; TYRPHOSTIN AG 957; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; APOPTOSIS; ARTICLE; BONE MARROW CELL; CELL STRAIN K 562; CHRONIC LYMPHATIC LEUKEMIA; CHRONIC MYELOID LEUKEMIA; CLONOGENESIS; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG MECHANISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 10744231785     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-02-0562     Document Type: Article

References (42)

1. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999;341:164-172.
2. Sawyers CL. Chronic meloid leukemia. N Engl J Med. 1999;340:1330-1340.
3. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996;2:561-566.
4. Dorsey JF, Jove R, Kraker AJ, Wu J. The pyrido-[2,3-d]pyrimidine derivative PD180970 inhibits p210Bcr-Abl tyrosine kinase and induces apoptosis of K562 leukemic cells. Cancer Res. 2000;60:3127-3131.
5. Kaur G, Gazit A, Levitzki A, Stowe E, Cooney DA, Sausville EA. Tyrphostin induced growth inhibition: correlation with effect on p210Bcr-abl autokinase activity in K562 chronic myelogenous leukemia. Anticancer Drugs. 1994;5:213-222.
6. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344:1031-1037.
7. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med. 2002;346:645-652.
8. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001;344:1038-1042.
9. O'Dwyer ME, Rosee PL, Nimmanapalli R, Bhalla KN, Druker BJ. Recent advances in Philadelphia chromosome-positive malignancies: the potential role of arsenic trioxide. Semin Hematol. 2002;39:18-21.
10. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293:876-880.
11. Hochhaus A, Kreil S, Corbin A, et al. Roots of clinical resistance to STI-571 cancer therapy. Science. 2001;293:2163.
12. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002;2:117-125.
13. La Rosee P, O'Dwyer ME, Druker BJ. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia. 2002;16:1213-1219.
14. Mow BMF, Chandra J, Svingen PA, et al. Effects of the Bcr/Abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro. Blood. 2002;99:664-671.
15. Nimmanapalli R, O'Bryan E, Huang M, et al. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 2002;62:5761-5769.
16. cbl phosphorylation in anti CD-3-stimulated T-lymphoblasts. Biochem Pharmacol. 1999;57:281-289.
17. Urbano A, Gorgun G, Foss F. Mechanisms of apoptosis by the tyrphostin AG957 in hematopoietic cells. Biochem Pharmacol. 2002;63:689-692.
18. Avramis IA, Christodoulopoulos G, Suzuki A, et al. In vitro and in vivo evaluations of the tyrosine kinase inhibitor NSC 680410 against human leukemia and glioblastoma cell lines. Cancer Chemother Pharmacol. 2002;50:479-489.
19. Svingen PA, Tefferi A, Kottke TJ, et al. Effects of the Bcr/abl kinase inhibitors AG957 and NSC 680410 on chronic myelogenous leukemia cells in vitro. Clin Cancer Res. 2000;6:237-249.
20. van Reyk DM, King NJ, Dinauer MC, Hunt NH, The intracellular oxidation of 2′,7′-dichlorofluorescin in murine T lymphocytes. Free Radic Biol Med. 2001;30:82-88.
21. Hildeman DA, Mitchell T, Teague TK, et al. Reactive oxygen species regulate activation-induced T cell apoptosis. Immunity. 1999;10:735-744.
22. Martins LM, Mesner PW, Kottke TJ, et al. Comparison of caspase activation and subcellular localization in HL-60 and K562 cells undergoing etoposide-induced apoptosis. Blood. 1997;90:4283-4296.
23. Kaufmann SH, Svingen PA, Gore SD, Armstrong DK, Cheng Y-C, Rowinsky EK. Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood. 1997;89:2098-2104.
24. Smith PK, Krohn RI, Hermanson GT, et al. Measurement of protein using bicinchoninic acid. Anal Biochem. 1985;150:76-85.
25. Kaufmann SH. Reutilization of immunoblots after chemiluminescent detection. Anal Biochem. 2001;296:283-286.
26. Pike BL, Robinson WA. Human bone marrow colony growth in agar-gel. J Cell Physiol. 1970;76:77-84.
27. Groskreutz JL, Bronk Sf, Gores GJ. Ruthenium red delays the onset of cell death during oxidative stress of rat hepatocytes. Gastroenterology. 1992;102:1030-1038.
28. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271-279.
29. Lazebnik YA, Kaufmann SH, Desnoyers S, Poirier GG, Earnshaw WC. Cleavage of poly(ADP-ribose)polymerase by a proteinase with properties like ICE. Nature. 1994;371:346-347.
30. Shen Y, White E. p53-Dependent apoptosis pathways. Adv Cancer Res. 2001;82:55-84.
31. Hickman JA. Apoptosis and tumourigenesis. Curr Opin Genet Dev. 2002;12:67-72.
32. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. Genes Dev. 1998;12:2973-2983.
33. Abraham RT. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001;15:2177-2196.
34. Anderson ME, Luo JL. Glutathione therapy: from prodrugs to genes. Semin Liver Dis. 1998;18:415-424.
35. Simizu S, Takada M, Umezawa K, Imoto M. Requirement of caspase-3(-like) protease-mediated hydrogen peroxide production for apoptosis induced by various anticancer drugs. J Biol Chem. 1998;273:26900-26907.
36. Garcia-Calvo M, Peterson EP, Leiting B, Ruel R, Nicholson DW, Thornberry NA. Inhibition of human caspases by peptide-based and macromolecular inhibitors. J Biol Chem. 1998;273:32608-32613.
37. Kaur G, Sausville EA. Altered physical state of p210bcr/abl in tyrphostin AG957-treated K562 cells. Anticancer Drugs. 1996;7:815-824.
38. + chronic myelogenous leukemia progenitor cells. Blood. 1999;93:3973-3982.
39. Sattler M, Verma S, Shrikhande G, et al. The BCR/ABL tyrosine kinase induces production of reactive oxygen species in hematopoietic cells. J Biol Chem. 2000;275:24273-24278.
40. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood. 1999;94:2102-2111.
41. Perkins C, Kim CN, Fang G, Bhalla KN. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood. 2000;95:1014-1022.
42. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TG. Bcr-Abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood. 1994;83:1179-1187.